Pooled analysis of six mature phase 3 trials (RESONATE2, ILLUMINATE, ALLIANCE041202, ELEVATE-TN, CLL14, and GLOW) evaluating Bruton's tyrosine kinase inhibitors (BTKis) and venetoclax-based treatments suggests that these agents have reduced but not completely eliminated the overall survival (OS) gap between elderly chronic lymphocytic leukemia (CLL) patients and the age and sex-matched general population (AGMGP).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.27182 | DOI Listing |
Publication Analysis
Top Keywords
chronic lymphocytic
8
lymphocytic leukemia
8
patients age
8
impact targeted
4
targeted agents
4
agents survival
4
survival chronic
4
leukemia patients
4
age >65
4
>65 relative
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!